Rifampicin
- Generic Name
- Rifampicin
- Brand Names
- Isonarif, Rifadin, Rifamate, Rifater, Rofact
- Drug Type
- Small Molecule
- Chemical Formula
- C43H58N4O12
- CAS Number
- 13292-46-1
- Unique Ingredient Identifier
- VJT6J7R4TR
- Background
A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericid...
- Indication
Rifampin is indicated for the treatment of tuberculosis and tuberculosis-related mycobacterial infections. In combination with pyrazinamide and isoniazid, it is used in the initial phase of the short-course treatment of pulmonary tuberculosis.
- Associated Conditions
- Cholestatic pruritus, MRSA Infections, Prosthetic Joint Infections, Asymptomatic Neisseria meningitidis carrier of the nasopharynx, Initial phase Tuberculosis, Late phase Tuberculosis
- Associated Therapies
- Antibacterial therapy
Drug-Drug Interaction and Food Effect of Sudapyridine(WX-081) With Itraconazole and Rifampin in Healthy Chinese Adults
- Conditions
- Interventions
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Shanghai Jiatan Pharmatech Co., Ltd
- Target Recruit Count
- 16
- Registration Number
- NCT06701136
A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2024-07-09
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Betta Pharmaceuticals Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06492525
- Locations
- 🇨🇳
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Irrisept vs Traditional Antibiotic Irrigation for Virgin Penile Prosthesis Placement
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-26
- Lead Sponsor
- Rush University Medical Center
- Target Recruit Count
- 100
- Registration Number
- NCT06489431
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸Uropartners Surgery Center, Des Plaines, Illinois, United States
A Study to Evaluate the Effect of Cytochrome P450 (CYP) 3A Inhibitor (Itraconazole) and Inducer (Rifampin) on the Drug Levels of Golcadomide (BMS-986369) in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-04-12
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Celgene
- Target Recruit Count
- 36
- Registration Number
- NCT06363630
- Locations
- 🇺🇸
Local Institution - 0002, Atlanta, Georgia, United States
🇺🇸Local Institution - 0001, Lenexa, Kansas, United States
Study to Evaluate the Drug-drug Interaction of JMKX001899 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Jemincare
- Target Recruit Count
- 72
- Registration Number
- NCT06348290
A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2024-03-27
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- Shouyao Holdings (Beijing) Co. LTD
- Target Recruit Count
- 28
- Registration Number
- NCT06332053
- Locations
- 🇨🇳
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Studies Evaluating the Effects of Itraconazole or Rifampicin on the Pharmacokinetics of TY-9591 Tablets in Healthy Subjects
- First Posted Date
- 2024-02-13
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- TYK Medicines, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT06255951
- Locations
- 🇨🇳
Yali Liu, Guangdong, Shantou, China
Shortened Regimen for Drug-susceptible TB in Children
- Conditions
- Interventions
- First Posted Date
- 2024-02-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 860
- Registration Number
- NCT06253715
- Locations
- 🇮🇳
Indian Council of Medical Research - National Institute for Research in Tuberculosis, Chennai, India
🇮🇳Dr. D.Y. Patil Medical College, Hospital and Research Center, Pimpri, Pune, India
🇮🇩Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
Novel Interventions and Diagnostic Tests for Leprosy
- First Posted Date
- 2024-01-24
- Last Posted Date
- 2024-01-24
- Lead Sponsor
- Annemieke Geluk
- Target Recruit Count
- 1100
- Registration Number
- NCT06222372
- Locations
- 🇧🇩
The Leprosy Mission International - Bangladesh, Nilphamari, Bangladesh
Drug Interaction Study
- Conditions
- Interventions
- First Posted Date
- 2024-01-08
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Emalex Biosciences Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT06194864
- Locations
- 🇨🇦
Syneos Health Clinic Inc., Québec, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.